Pharmacoeconomic review report: AbobotulinumtoxinA (Dysport therapeutic) (Ipsen biopharmaceuticals Canada, Inc.) indication, for the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older
AbobotulinumtoxinA (aboBoNTA) is a botulinum toxin that blocks nerve activity in the muscles, causing a temporary reduction in muscle activity. The recommended starting dosage of aboBoNTA for pediatric patients with lower-limb spasticity (LLS) is 10 U/kg to 15 U/kg for unilateral lower-limb injectio...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, August 2018
|
Edition: | Version: Final with redactions |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | AbobotulinumtoxinA (aboBoNTA) is a botulinum toxin that blocks nerve activity in the muscles, causing a temporary reduction in muscle activity. The recommended starting dosage of aboBoNTA for pediatric patients with lower-limb spasticity (LLS) is 10 U/kg to 15 U/kg for unilateral lower-limb injections, or 20 U/kg to 30 U/kg for bilateral lower-limb injections per treatment session. Treatment can be administered to multiple sites of muscles within the lower limb. If the treatment effect from the first dose diminishes over time, patients can be re-treated after a period of at least 12 weeks. The manufacturer submitted a cost-utility analysis comparing aboBoNTA with onabotulinumtoxinA (onaBoNTA) in pediatric patients two years of age or older with unilateral or bilateral LLS. |
---|---|
Physical Description: | 1 PDF file (26 pages) illustrations |